Health

Chad Launches Historic Triple Vaccine Rollout to Protect Millions of Children

In a groundbreaking move, Chad has embarked on an ambitious triple vaccine rollout, including the WHO-recommended R21 malaria vaccine, to safeguard the health and well-being of millions of children. This initiative targets 19.7 million children aged between six months and five years, with 168,522 children between six and 15 months receiving the malaria vaccine in 28 priority districts ¹.

The R21 malaria vaccine, developed by the University of Oxford and the Serum Institute of India, has shown high efficacy in clinical trials, with a 75% success rate in preventing malaria in children ¹. This vaccine is a game-changer in the fight against malaria, which remains endemic in Chad, accounting for 43% of medical consultations, 36% of hospitalizations, and 30% of hospital deaths.

Chad’s efforts are supported by the World Health Organization (WHO), GAVI, the Vaccine Alliance, UNICEF, and the Gates Foundation. The country has received 157,900 doses of the R21 vaccine, marking a significant step forward in its fight against malaria.

Key Highlights of the Rollout:

  • Target Population:- 19.7 million children aged between six months and five years
  • Malaria Vaccine Recipients:- 168,522 children between six and 15 months in 28 priority districts
  • Vaccine Doses:- 157,900 doses of the R21 vaccine received
  • Supporting Partners:- WHO, GAVI, UNICEF, and the Gates Foundation

Dr. Anya Blanche-Philomene Malanga, WHO Representative in Chad, hailed the launch as “a very important day for Chad and its children.” She emphasized that malaria vaccines are a breakthrough for child health and malaria control, and will save tens of thousands of young lives every year.

With this rollout, Chad joins 13 other African countries offering malaria vaccination, extending access to more comprehensive malaria prevention. The initiative is a testament to the country’s commitment to protecting its children and combating the devastating impact of malaria.

WHO/Ruth Abla ADJORLOLO

Leave a Comment

Your email address will not be published. Required fields are marked *

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.